Equities

Cardio Diagnostics Holdings Inc

CDIO:NAQ

Cardio Diagnostics Holdings Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.28
  • Today's Change0.000 / 0.07%
  • Shares traded312.65k
  • 1 Year change-26.51%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Cardio Diagnostics Holdings Inc share price to rise to 2.00 in the next year from the last price of 0.28.
High614.3%2.00
Med614.3%2.00
Low614.3%2.00

Earnings history & estimates in USD

On Aug 12, 2024, Cardio Diagnostics Holdings Inc reported 2nd quarter 2024 losses of -0.06 per share. This result exceeded the -0.11 consensus loss of the 2 analysts covering the company and exceeded last year's 2nd quarter results by 84.62%.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate+64.49%
Cardio Diagnostics Holdings Inc reported annual 2023 losses of -0.66 per share on Apr 01, 2024.
Average growth rate+56.29%
More ▼

Revenue history & estimates in USD

Cardio Diagnostics Holdings Inc had 2nd quarter 2024 revenues of 8.00k. This missed the 113.00k consensus estimate of the 2 analysts following the company. This was 300.00% above the prior year's 2nd quarter results.
Average growth rate+130.00%
Cardio Diagnostics Holdings Inc had revenues for the full year 2023 of 17.00k. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.